Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS)

被引：4
|
作者：
Cheema, P. [1 ]
Passaro, A. [2 ]
Martin, C. [3 ]
Tiseo, M. [4 ]
Park, K. [5 ]
Chang, G. [6 ,7 ,8 ]
Hu, Y. [9 ]
Cho, B. C. [10 ]
Miranda, M. [11 ]
Fernandes, A. [12 ]
Freitas, H. [13 ]
机构：
[1] Univ Toronto, Sunnybrook Odette Canc Ctr, William Osler Hlth Syst, Toronto, ON, Canada
[2] European Inst Oncol Irccs, Ieo, Div Thorac Oncol, Milan, Italy
[3] Inst Alexander Fleming, Dept Oncol, Buenos Aires, DF, Argentina
[4] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea
[6] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan
[7] Taichung Vet Gen Hosp, Fac Med, Sch Med, Taichung, Taiwan
[8] Natl Yang Ming Univ, Taichung, Taiwan
[9] Hubei Canc Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[11] Astrazeneca, Biometr & Informat Sci, Cambridge, England
[12] Astrazeneca Us, Gaithersburg, MD USA
[13] AC Camargo Canc Ctr, Clin Res Unit, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
NSCLC; EGFR; Osimertinib;
D O I：
10.1016/j.jtho.2019.08.1844
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.14-59
引用
收藏
页码：S854 / S854
页数：1
相关论文
共 50 条
  • [21] Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
    Zhang, X.
    Wu, Y-L.
    Chen, Y.
    Zhang, H.
    Wu, G.
    Lu, Y.
    Liang, Z.
    Hu, Y.
    Cheng, Y.
    Wang, J.
    Ying, J.
    Liu, W.
    Liang, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1537 - S1537
  • [22] Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
    Papadimitrakopoulou, V. A.
    Wu, Y-L.
    Han, J-Y.
    Ahn, M-J.
    Ramalingam, S. S.
    John, T.
    Okamoto, I.
    Yang, J. C-H.
    Bulusu, K. C.
    Laus, G.
    Collins, B.
    Barrett, J. C.
    Chmielecki, J.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 741 - 741
  • [23] Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
    Schmid, S.
    Klingbiel, D.
    Aeppli, S.
    Britschgi, C.
    Gautschi, O.
    Pless, M.
    Rothschild, S.
    Wannesson, L.
    Janthur, W.
    Foerbs, D.
    Demmer, I.
    Jochum, W.
    Fruth, M.
    LUNG CANCER, 2019, 130 : 149 - 155
  • [24] Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
    Zhao, Sha
    Li, Xuefei
    Zhao, Chao
    Jiang, Tao
    Jia, Yijun
    Shi, Jinpeng
    He, Yayi
    Li, Jiayu
    Zhou, Fei
    Gao, Guanghui
    Li, Wei
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    LUNG CANCER, 2019, 128 : 33 - 39
  • [25] A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG)
    Miura, S.
    Hsia, T.
    Hung, J.
    Jung, H. A.
    Shih, J.
    Park, C.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1115 - S1116
  • [26] Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
    Cao, Y.
    Qiu, X.
    Xiao, G.
    Hao, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
    Watanabe, Kana
    Saito, Ryota
    Miyauchi, Eisaku
    Nagashima, Hiromi
    Nakamura, Atsushi
    Sugawara, Shunichi
    Tanaka, Nobuyuki
    Terasaki, Hiroshi
    Fukuhara, Tatsuro
    Maemondo, Makoto
    CANCERS, 2023, 15 (17)
  • [28] Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
    Cao, Yabing
    Qiu, Xibin
    Xiao, Guangli
    Hu, Hao
    Lin, Tongyu
    PLOS ONE, 2019, 14 (08):
  • [29] Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
    Yang, Zhengquan
    Li, Jialu
    Hu, Yujie
    Chen, Meihua
    Peng, Danli
    Zong, Dan
    Shang, Qingjuan
    Tao, Lianqin
    Zhao, Yanling
    Ni, Yiyun
    Ye, Jinyan
    Xie, Yupeng
    Yang, Li
    Lin, Quan
    Cai, Chang
    Xu, Ning
    Huang, Xiaoping
    Dong, Xiaoting
    Zhou, Zhonghui
    Yu, Yali
    Shangguan, Zongxiao
    Xu, Yangyang
    Ying, Weiping
    Weng, Meiling
    Yuan, Zuguo
    Dong, Zhijun
    Li, Jifa
    Zheng, Zhe
    Pan, Jiongwei
    Liu, Lu
    Ye, Junhui
    Zhang, Zhan
    Li, Wenfeng
    Zhu, Junfei
    Jin, Shengnan
    Li, Yuping
    Ding, Chunming
    TARGETED ONCOLOGY, 2019, 14 (06) : 719 - 728
  • [30] Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
    Zhengquan Yang
    Jialu Li
    Yujie Hu
    Meihua Chen
    Danli Peng
    Dan Zong
    Qingjuan Shang
    Lianqin Tao
    Yanling Zhao
    Yiyun Ni
    Jinyan Ye
    Yupeng Xie
    Li Yang
    Quan Lin
    Chang Cai
    Ning Xu
    Xiaoping Huang
    Xiaoting Dong
    Zhonghui Zhou
    Yali Yu
    Zongxiao Shangguan
    Yangyang Xu
    Weiping Ying
    Meiling Weng
    Zuguo Yuan
    Zhijun Dong
    Jifa Li
    Zhe Zheng
    Jiongwei Pan
    Lu Liu
    Junhui Ye
    Zhan Zhang
    Wenfeng Li
    Junfei Zhu
    Shengnan Jin
    Yuping Li
    Chunming Ding
    Targeted Oncology, 2019, 14 : 719 - 728
12345